Loading...
Loading...
- AdaptHealth Corp AHCO delivered Q3 revenue of $756.5 million, +15.8% Y/Y, beating the consensus of $737.94 million.
- Adjusted EBITDA reached $160.2 million, +2.5% Y/Y.
- Steve Griggs, Chief Executive Officer, commented, "We delivered another solid quarter as we continued to capitalize on strong demand in our HME and Sleep product lines with CPAP patient set-ups at or near record levels each month of the quarter, and our diabetes product line once again posting double-digit growth."
- The company reported EPS of $0.11, down from $0.20 a year ago and the consensus of $0.31.
- Cash flow from operations was $107 million.
- Guidance: AdaptHealth revised FY22 sales to $2.95-$3.01 billion compared to $2.84 - $3.04 billion expected earlier versus the consensus of $2.95 billion.
- It has tightened the adjusted EBITDA forecast to $620-$650 million from $615-$675 million.
- Price Action: AHCO shares are down 1.99% at $20.64 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in